Q2 revenue grew 43% year-over-year, driven by strong Afrezza and FUROSCIX sales, with pediatric Afrezza launch showing robust early adoption and FUROSCIX ReadyFlow set for imminent launch. Investments in launches and R&D led to a net loss, but cash position remains strong.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.